Watch for the definitive agreement by November 30, 2026 — failure to close would void the term sheet. Monitor TIRC's progress toward manufacturing, nonclinical, and regulatory milestones, and any further equity draws under the White Lion facility to fund the development program.
Price Chart
Executive Summary
Psyence Biomedical's wholly-owned Texas subsidiary, TIRC, entered a binding term sheet with PsyLabs for exclusive U.S. rights to pharmaceutical-grade ibogaine HCl, including IP license, supply, and distribution. The deal involves up to ~$1.3M in milestones for the first drug candidate, a low single-digit royalty, and an annual exclusivity fee post-FDA approval, but is a related-party transaction with no near-term revenue catalyst and a November 30, 2026 deadline for a definitive agreement. The filing is neutral: it secures a strategic position in U.S. ibogaine development but offers no financial data, no approved products, and the company remains pre-revenue with heavy cash burn and reliance on equity dilution.
Key Facts
- Binding term sheet signed September 25, 2026, between TIRC (wholly-owned Texas subsidiary of PBM) and PsyLabs for exclusive U.S. license, supply, and distribution of pharmaceutical-grade ibogaine HCl.
- Milestone payments totaling up to approximately US$1.3 million for the first drug candidate; specific amounts redacted.
- Low single-digit percentage royalty on net sales of each drug candidate; annual exclusivity fee creditable against royalties, commencing on first anniversary of first FDA approval.
- Definitive agreement must be concluded by November 30, 2026, or term sheet lapses; PsyLabs is a significant shareholder of PBM and the transaction is a related-party deal.
- PBM remains pre-revenue with no FDA-approved products; prior 20-F (June 2026) reported net loss of $6.89M, cash of $7.49M, and reliance on a $100M equity line of credit.
Financial Impact
Up to ~$1.3M in milestone payments for first drug candidate; royalty and exclusivity fee amounts redacted; no upfront cash consideration disclosed.
Risk Factors
- Definitive agreement may not be concluded by November 30, 2026, causing the term sheet lapse.
- Related-party transaction is a related-party transaction; terms may not reflect arms-length pricing.
- Ibogaine remains a controlled substance; FDA approval not guaranteed and clinical pathway uncertain.
- Company is pre-revenue with widening losses and heavy reliance on dilutive equity financing.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-103733 |
| Document: ea030680701ex99-1.htm | 0001213900-26-103733 |
| Document: ea0306807-6k_psyence.htm | 0001213900-26-103733 |
| Document: 0001213900-26-103733-index-headers.html | 0001213900-26-103733 |
| Document: 0001213900-26-103733-index.html | 0001213900-26-103733 |
| Document: 0001213900-26-103733.txt | 0001213900-26-103733 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $4.52 $4.12 | ▼ −8.85% | ▼ −7.67% | $3.66 (−19.03%) |
Oct 15, 2026 11d ago | SC 13D/A | $4.32 $4.22 | ▼ −2.31% | ▼ −1.21% | $3.66 (−15.28%) |
Oct 5, 2026 21d ago | SC 13G | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Oct 5, 2026 21d ago | 6-K | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Oct 5, 2026 21d ago | Press Release | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Sep 28, 2026 28d ago | 6-K | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.66 (−35.39%) |
Sep 28, 2026 28d ago | Press Release | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.66 (−35.39%) |
Sep 23, 2026 4w ago | 6-K | $6.31 $5.86 | ▲ +7.13% | ▲ +7.05% | $3.66 (+42.00%) |
Sep 14, 2026 6w ago | 6-K | $6.00 $6.07 | ▲ +1.17% | ▲ +1.63% | $3.66 (−39.00%) |
Sep 2, 2026 7w ago | EFFECT | $4.37 $4.43 | ▲ +1.37% | ▲ +0.33% | $3.66 (−16.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers